Leqembi launch hamstrung by physicians' 'therapeutic nihilism'
FiercePharma - 23 Apr 2024Leqembi launch hamstrung by physicians' 'therapeutic nihilism' ...
エーザイ
Leqembi launch hamstrung by physicians' 'therapeutic nihilism' ...
BioArctic and Eisai look beyond Leqembi in Alzheimer's
The Pharma Letter - 23 Apr 2024BioArctic and Eisai look beyond Leqembi in Alzheimer's ...
BioArctic partners with Eisai on Alzheimer's treatment
GlobalData - 22 Apr 2024BioArctic partners with Eisai on Alzheimer's treatment ...
Biogen and Eisai Fall Behind on Leqembi’s Subcutaneous BLA for Alzheimer’s
BioSpace - 01 Apr 2024Biogen and Eisai Fall Behind on Leqembi’s Subcutaneous BLA for Alzheimer’s ...
Alzheimer's drug Leqembi falls short of blockbuster status in faltering US rollout
Financial Times - 22 Apr 2024Alzheimer's drug Leqembi falls short of blockbuster status in faltering US rollout ...
Eisai seeks FDA approval of Leqembi IV maintenance dosing
Alzheimer's News Today - 04 Apr 2024Eisai seeks FDA approval of Leqembi IV maintenance dosing ...
Eisai signs agreement to divest rights for two therapies to Kaken
Pharmaceutical Technology - 02 Apr 2024Eisai signs agreement to divest rights for two therapies to Kaken ...
Medicare expects spending spike for Biogen, Eisai Alzheimer's drug- STAT
STAT - 15 Apr 2024Medicare expects spending spike for Biogen, Eisai Alzheimer's drug- STAT ...
EU regulator delays decision on Eisai-Biogen Alzheimer's drug
Reuters - 22 Mar 2024EU regulator delays decision on Eisai-Biogen Alzheimer's drug ...
Eisai to Host Annual Information Meeting with Update on LEQEMBI® (lecanemab-irmb) | Biogen
Biogen - 07 Mar 2024Eisai to Host Annual Information Meeting with Update on LEQEMBI® (lecanemab-irmb) | Biogen ...
Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV ...
Yahoo Finance - 31 Mar 2024Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV ... ...
Eisai to drop up to $15M on C2N Diagnostics to boost the reach of Alzheimer's disease blood tests
Fierce Biotech - 06 Mar 2024Eisai to drop up to $15M on C2N Diagnostics to boost the reach of Alzheimer's disease blood tests ...
Eisai, Biogen's subQ Leqembi delayed amid FDA's data request
FiercePharma - 01 Apr 2024Eisai, Biogen's subQ Leqembi delayed amid FDA's data request ...
Eisai and Biogen move to bring IV maintenance dosing for Leqembi to the US
Pharmaceutical Technology - 01 Apr 2024Eisai and Biogen move to bring IV maintenance dosing for Leqembi to the US ...
Japan's Eisai says US introduction of Alzheimer's drug Leqembi slower than expected
Reuters - 07 Mar 2024Japan's Eisai says US introduction of Alzheimer's drug Leqembi slower than expected ...
Eisai supports creation of Alzheimer's podcast miniseries
FiercePharma - 12 Apr 2024Eisai supports creation of Alzheimer's podcast miniseries ...
Exclusive: Eisai expects 1500 Alzheimer's patients in China launch, sees 'huge' growth
Reuters - 05 Feb 2024Exclusive: Eisai expects 1500 Alzheimer's patients in China launch, sees 'huge' growth ...
Eisai, Carvykti, Ozempic biosimilar—Fierce Pharma Asia
FiercePharma - 05 Apr 2024Eisai, Carvykti, Ozempic biosimilar—Fierce Pharma Asia ...
Fierce Pharma Asia—Eisai's Leqembi outlook; Sumitomo's downsizing; Kyowa Kirin's expansion
FiercePharma - 08 Mar 2024Fierce Pharma Asia—Eisai's Leqembi outlook; Sumitomo's downsizing; Kyowa Kirin's expansion ...